Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice.

Authors:
Cuddy LK; Alia AO; Salvo MA; Chandra S; Grammatopoulos TN and 4 more

Journal:
Mol Neurodegener

Publication Year: 2022

DOI:
10.1186/s13024-022-00561-9

PMCID:
PMC9392365

PMID:
35987691

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Mol Neurodegener

Abbreviation: Mol Neurodegener

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Molecular Biology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
APOE4 genotype and aging impair injury-induced microglial behavior in brain slices, including towar…
Sepulveda J; Kim JY; Binder J and 2 more (2024) - Transparency Score: 3/6
Cognitive, functional, and neuropsychiatric correlates of regional tau pathology in autopsy-confirm…
Alosco ML; White M; Bell C and 21 more (2024) - Transparency Score: 3/6
Collagen in the central nervous system: contributions to neurodegeneration and promise as a therape…
Wareham LK; Baratta RO; Del Buono BJ and 2 more (2024) - Transparency Score: 2/6
CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegene…
Mravinacová S; Alanko V; Bergström S and 8 more (2024) - Transparency Score: 3/6
Fluid biomarkers for amyotrophic lateral sclerosis: a review.
Irwin KE; Sheth U; Wong PC and 1 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateAll animal work was done in accordance with Northwestern University Institutional Animal Care and Use Committee (IACUC) approval. Consent for publicationNot applicable. Competing interestsJRM is a scientific co-founder of Lysosomal Therapeutics, INC. Competing interests JRM is a scientific co-founder of Lysosomal Therapeutics, INC."

Evidence found in paper:

"Funding This work was supported by NIH R01 AG030142."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025